In the U.S., about 6% of adults currently use GLP-1s, and 12% have used them in the past (2024 data) (Mozafariun 2025)
Central Nervous System Appetite Modulation GLP-1 signaling also influences neural pathways involved in hunger and reward processing, as documented in clinical pharmacology research published in the NCBI [2] literature on incretin-based therapies
This is clinically meaningful as we know that we can reduce the risk of diabetes related completions through achievement and maintenance of glycemic targets, with the target of less than 7% as the generally accepted standard, Aroda said
Indian Journal of Plastic Surgery, 54 (4), 477482
De Regil, World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults, JAMA , Dec
Our free 3-minute DiabeSCORE quiz analyses your symptoms, lifestyle, and risk factors to give you a personalised metabolic health score and tells you exactly where your GLP-1 system may need support